Publications by authors named "Y Ngai"
Article Synopsis
- The study focused on the long-term effects of afatinib in patients with EGFR mutant non-small cell lung cancer (NSCLC) who also had other health issues, and assessed the usefulness of monitoring circulating tumor DNA (ctDNA).
- Conducted in the UK, the TIMELY trial involved patients receiving afatinib daily until their disease progressed or they experienced significant side effects, with blood samples analyzed every 12 weeks.
- Results showed that while the median progression-free survival was 7.9 months, some patients experienced long-term benefits, and ctDNA testing improved the detection of EGFR mutations and was linked to better outcomes.
Article Synopsis
- An immunotherapy targeting the 5T4 tumor antigen was tested in a clinical trial to determine if it could delay chemotherapy in patients with asymptomatic relapsed ovarian cancer.
- The phase II study, TRIOC, was randomized, placebo-controlled, and aimed to evaluate both the effectiveness and safety of the MVA-5T4 treatment among patients meeting specific eligibility criteria.
- Results showed that the median progression-free survival was similar for both the MVA-5T4 group (59 patients) and placebo group (35 patients), with an 80% progression rate for MVA-5T4 compared to 85.7% for placebo, indicating no significant advantage for the immunotherapy.
Rationale: The application of matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) to murine lungs is challenging due to the spongy nature of the tissue. Lungs consist of interconnected air sacs (alveoli) lined by a single layer of flattened epithelial cells, which requires inflation to maintain its natural structure. Therefore, a protocol that is compatible with both lung instillation and high spatial resolution is essential to enable multi-omic studies on murine lung disease models using MALDI-MSI.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates how different variants of SARS-CoV-2 and host characteristics, like age and prior immunity, influence the virus's replication and transmission in individuals from 2020 to 2022.
- Researchers used a Bayesian hierarchical model to analyze data from healthy adults undergoing regular PCR testing, focusing on viral kinetics indicated by PCR cycle threshold (Ct) values.
- Findings showed that older individuals and those with more prior exposures exhibited lower viral shedding, highlighting the need to consider individual characteristics when studying COVID-19 dynamics.
CD19-negative relapse is a leading cause of treatment failure after chimeric antigen receptor (CAR) T-cell therapy for acute lymphoblastic leukemia. We investigated a CAR T-cell product targeting CD19 and CD22 generated by lentiviral cotransduction with vectors encoding our previously described fast-off rate CD19 CAR (AUTO1) combined with a novel CD22 CAR capable of effective signaling at low antigen density. Twelve patients with advanced B-cell acute lymphoblastic leukemia were treated (CARPALL [Immunotherapy with CD19/22 CAR Redirected T Cells for High Risk/Relapsed Paediatric CD19+ and/or CD22+ Acute Lymphoblastic Leukaemia] study, NCT02443831), a third of whom had failed prior licensed CAR therapy.
View Article and Find Full Text PDF